SCHEMBL13061368

SCHEMBL13061368

CCCc1ccc(CN2CCN(C)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.65
MC4R P32245 1/20 0.63
CHKA P35790 6/20 0.61
NPC1 O15118 2/20 0.58
TP53 P04637 2/20 0.58
RAB9A P51151 2/20 0.58
HPGD P15428 1/20 0.58
CA2 P00918 1/20 0.57
NCF1 P14598 1/20 0.57
PRMT6 Q96LA8 1/20 0.57
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 2/20 0.54
MBTD1 Q05BQ5 1/20 0.53
L3MBTL3 Q96JM7 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HRH3 Q9Y5N1 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21650862 0.89 NPC1 (0.63) LMNAMC4RCHKANPC1TP53
SCHEMBL17465319 0.89 CHKA (0.82) CHKACA2NCF1PRMT6KDM4E
SCHEMBL13228061 0.84 HRH3 (0.68) NCF1KDM4EALDH1A1MBTD1L3MBTL3
SCHEMBL306744 0.84 LMNA (0.69) LMNAMC4RCHKANPC1TP53
SCHEMBL25565610 0.84 ALDH1A1 (0.66) LMNANPC1TP53RAB9AHPGD
SCHEMBL5912658 0.83 LMNA (0.73) LMNAMC4RCHKANPC1TP53
SCHEMBL15390746 0.83 LMNA (0.62) LMNAMC4RCHKANPC1TP53
SCHEMBL13062773 0.82 HRH3 (0.72) NCF1KDM4EALDH1A1MBTD1L3MBTL3
SCHEMBL18753409 0.82 MC4R (0.61) LMNAMC4RCHKANPC1TP53
Hydrochloric Acid SCHEMBL3868716 0.81 LMNA (0.71) LMNAMC4RCHKANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3241554-A1 QUINOLINE-8-SULFONAMIDE DERIVATES HAVING AN ANTICANCER ACTIVITY Agios Pharmaceuticals, Inc. (US) 2017-11-08 EP disclosed
US-20100317644-A1 Substituted Sulfonamide Compounds GRUENENTHAL GMBH (DE) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317644-A1 Substituted Sulfonamide Compounds SULT2A1, STS, SULT1A1 LMNA 2964/4885MC4R 1834/4885CHKA 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.